RxDoctor Payments Data

Guy Racette, MD

Occupational Medicine · Corpus Christi, TXNPI 1801876255

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 74 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 12 manufacturers reported payments, led by Lilly USA, LLC at 26.9% of the total. Among occupational medicine clinicians in TX with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$1,335in general payments, 2019–2025

Across 74 payments — averaging $18.04 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$359
  • GSK$292
  • Novo Nordisk$254
  • AstraZeneca$99
  • Exact Sciences$71
  • Pfizer$55
  • plus $206 from 6 others

What the payments were for

  • Food & beverage$1,335100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,335 in reported general payments places this provider in the 90th percentile of 51 occupational medicine providers in Texas.

See all occupational medicine providers in Texas

Medicare billing

Part B allowed, 2024
$27,724
Medicare patients
139
Services billed
376

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XareltoRivaroxaban16$16,082
OzempicSemaglutide14$14,097
EliquisApixaban15$14,075
LinzessLinaclotide13$12,183
Trelegy ElliptaFluticasone/Umeclidin/Vilanter16$11,148
Albuterol Sulfate HfaAlbuterol Sulfate25$1,103
Gabapentin60$991
Atorvastatin Calcium115$835
Acetaminophen-CodeineAcetaminophen With Codeine24$743
Levothyroxine Sodium85$714
Lisinopril108$577
Duloxetine Hcl16$412
Buspirone Hcl22$403
Losartan Potassium52$399
Metoprolol Succinate38$398

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$254$14,09714 claims
PfizerEliquis$55$14,07515 claims
GSKTrelegy Ellipta$292$11,14816 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 51 occupational medicine providers in Texas.

Other occupational medicine in Corpus Christi

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →